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Abstract
Background and Aims: Ulcerative colitis [UC] is a chronic inflammatory disease that effects 
the gastrointestinal tract and is considered one of the most prominent and common forms of 
inflammatory bowel disease [IBD]. This study aimed to define and describe the entire transcriptomic 
landscape in a well-stratified, treatment-naïve UC patient population compared with control 
patients by using next-generation technology, RNA-Seq.
Methods: Mucosal biopsies from treatment-naïve UC patients [n  =  14], and healthy controls 
[n = 16] underwent RNA-Seq. Principal component analysis [PCA], cell deconvolution methods, 
and diverse statistical methods were applied to obtain and characterise a dataset of significantly 
differentially expressed genes [DEGs].
Results: Analyses revealed 1480 significantly DEGs in treatment-naïve UC when compared with 
controls. Cell populations of monocytes, T cells, neutrophils, B cells/ lymphoid cells, and myeloid 
cells were increased during inflammation, whereas the fraction of epithelial cells were reduced 
in UC, which is reflected by the DEGs; 79 DEGs were identified as IBD susceptibility genes, and 
58 DEGs were expressed in a gender-specific manner. MUC5B, REG3A, DEFA5, and IL33 might 
be considered as colorectal cancer [CRC] risk factors following UC in males. AQP9 together with 
CLDN2 may have a role regulating tissue-specific physiological properties in tight junctions in 
UC. An additional functional role for AQP9 in the synthesis and/or the function of mucus can be 
implied.
Conclusions: This study reveals new potential players in UC pathogenesis in general, and 
provides evidence for a gender-dependent pathogenesis for UC. These results can be useful for the 
development of personalised treatment strategies for UC in the future.
Key Words:  Gender; RNA-Seq; ulcerative colitis [UC]
1. Introduction
Ulcerative colitis [UC] is a chronic inflammatory disorder of the gas-
trointestinal tract, and along with Crohn’s disease [CD] comprise 
two of the common forms of inflammatory bowel disease [IBD]. In 
contrast to CD, the inflammations in UC are limited to the mucosa 
and submucosa of the colon, and the rectum.1 Chronic inflammations 
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have been shown to increase the risk for the development of colo-
rectal cancer [CRC].2 Just 10–20% of IBD cases can be explained by 
genetic variances,3,4 suggesting a much more complex pathogenesis, 
perhaps an underlying interplay between environmental factors, the 
intestinal microbiome, nutrition, and genetic factors. Susceptibility 
genes are responsible for triggering a dysregulation of the immune 
system and affecting the gut barrier function.5,6 Nevertheless, despite 
decades of investigation, the complex pathogenesis of IBD is not 
fully understood.
Many attempts have been made to describe transcriptional 
levels in UC,7–9 usually by using hybridisation-based methods like 
microarrays.10 These methods are restricted to predefined and often 
well-annotated RNA species. Next-generation sequencing [NGS] 
techniques [RNA-Seq] have no such restrictions. One recent report 
used RNA-Seq for gene expression profiling in patients with IBD 
including patients with different treatment strategies.11 For the pre-
sent study, a clearly defined group of newly diagnosed [treatment-
naïve] UC patients was used. It is believed that RNA-Seq, together 
with well-stratified UC patient material, can potentially provide a 
more comprehensive and correct transcriptomic profile of UC. The 
results of this study do not only reveal new potential players in treat-
ment-naïve UC pathogenesis in general, but in addition provide evi-
dence of a gender-dependent pathogenesis for UC. These results can 
be useful for the development of general and/or gender-dependent 
treatment strategies for UC in the future.
2. Material and Methods
2.1. Patient material
A standardised sampling method was used to collect mucosal biop-
sies from the colon of 14 newly diagnosed, treatment-naïve UC 
patients with mild to moderate disease activity and from 16 con-
trols. Samples from subjects performing a cancer screening, with 
normal colonoscopy and normal colonic histological examination, 
served as controls. UC was diagnosed based upon established clini-
cal endoscopic and histological criteria as defined by the ECCO 
guidelines.12 The grade of inflammation was assessed during colo-
noscopy using the UC Disease Activity Index [UCDAI] endoscopic 
sub-score with 3 to 10 for mild to moderate disease.13 Apart from 
one rectal control sample, all biopsies were taken from the sigmoid 
part of the colon. Tumour necrosis factor alpha [TNF-α] mRNA 
expression levels were measured by real-time polymerase chain 
reaction [PCR], thereby indicating the grade of UC activity.14 The 
samples were taken from an established Biobank approved by the 
Norwegian Board of Health. All patient characteristics are depicted 
in Table 1. The participants signed an informed and written consent 
form. The study was approved by the Regional Ethics Committee 
of North Norway and the Norwegian Social Science Data Services 
[REK Nord 2012/1349].
2.2. DNA and RNA isolation
Total RNA was isolated using the Allprep DNA/RNA Mini Kit from 
Qiagen [Cat. No.:  80204] and the QIAcube instrument [Qiagen], 
according to the manufacturer’s protocol. RNA quantity and purity 
were assessed by using the NanoDrop ND-1000 spectrophotom-
eter [ThermoFisher Scientific, Wilmington, DE, USA]. The Experion 
Automated Electrophoresis System [Bio-Rad, Hercules, CA, USA] 
and the RNA StdSens Analysis Kit [Bio-Rad, cat. No.: 700–7103] 
was used to evaluate RNA integrity, according to the instruction 
manual. RNA samples were kept at −70°C until further use. All RNA 
samples used for analyses had a RIN value between 8.0 and 10.0.
2.3. Quantitative polymerase chain reaction
The TNF-α levels in biopsies were measured by using quantitative 
polymerase chain reaction [qPCR]. RNA quantity was assessed with 
NanoVue Plus [GE Healthcare, UK]. Synthesis of cDNA was per-
formed using the QuantiTect Reverse Transcription Kit [Qiagen, cat. 
No.:  205314], and the QuantiNova Probe PCR Kit [Qiagen, cat. 
No.: 208256]. Beta-actin [β-actin] was used as housekeeping gene. 
For the detection, a CFX Connect Real Time PCR Detection System 
[Bio-Rad, USA] was used. The results were measured in copies/µg. 
Values < 7000 copies/µg protein are considered as non-inflamed tis-
sues, and values > 7000 copies/µg protein are considered inflamed 
tissues.14
2.4. Library preparation & Next generation 
sequencing
Transcriptome libraries were prepared with the TruSeq Stranded 
Total RNA LT Sample Prep Kit from Illumina [Cat. No.: RS-122–
2203]. The amount of input material was 1 µg of total RNA. The 
Bioanalyzer 2100 [Agilent Technologies, Santa Clara, USA], and 
the Agilent DNA 1000 kit [Cat. No.: 5067-1504] were used to 
assess RNA libraries quality, according to the instruction manual. 
The RNA libraries comprised fragments with an average size of 
307 base pairs. The libraries were normalised to 10 nM and subse-
quently sequenced with the NextSeq 550 instrument [Illumina, USA] 
according to the manufacturer’s instructions. The average number 
of uniquely mapped reads per sequencing run was 88 million reads 
per sample.
2.5. Data analysis
Base calling and quality scoring were performed as a first step 
including quality check on the on-board computer of the NextSeq 
550. The algorithm packages STAR-2.5.2b and the htseq-count were 
used for downstream analysis.15 Transcripts were aligned to human 
genome assembly GRCH38p.11 [https://www.ncbi.nlm.nih.gov/grc/
human/data]. Read counts were transformed using the DESeq2-
Rlog variance stabilised transform, and significantly differentially 
expressed transcripts were identified by including transcripts with a 
read count of > 30 and fold change > 2 as compared with controls. 
Additional annotation was added using the PANTHER classification 
system [http://pantherdb.org/], the Kyoto Encyclopaedia of Genes 
and Genomes [KEGG] [www.genome.jp/kegg/], and the human 
gene database GeneCards [http://www.genecards.org/]. For princi-
pal component analysis [PCA], the top 5000 most variable of the 
DESeq2-Rlog variance stabilised genes were used. For the estimation 
of specific cell populations in patient samples, all DESeq2-Rlog nor-
malised transcripts with a log2 average mean > 5 were included. The 
analysis was performed using the R/Bioconductor CellMix manual 
[http://web.cbio.uct.ac.za/~renaud/CRAN/web/CellMix/] with the 
Table 1. Demographic information of patient samples.
Characteristics Control group  
[n = 16]
Ulcerative colitis  
[n = 14]
Male/female 11/5 9/5
Age mean ± SD, years 52.9 ± 16.9 39.57 ± 15.24
Endo score mean ± SD 0 1.93 ± 0.27
Clinical score ± SD 0 7.23 ± 2.45
TNF-α level ± SD 3663 ± 1973 15907 ± 9623
SD, standard deviation; TNF, tumour necrosis factor.
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IRIS [Immune Response In Silico] weighted marker list characteristic 
for the different cell types.16 Epithelial markers cadherin 1 [CDH1], 
epithelial cell adhesion molecule [EPCAM], phosphatidylinositol 
glycan anchor biosynthesis class F [PIGF], L1 cell adhesion molecule 
[L1CAM], and laminin subunit alpha 1 [LAMA1] were added to the 
IRIS marker list and weighted strongly to give an estimate of epi-
thelial presence in samples. The contrast matrix [[Nfemale - UCfemale] - 
[Nmale - UCmale]] was used in DESeq2 to determine differentially 
regulated genes between UC and controls which differed signifi-
cantly between male and female. Results were limited to adjusted 
p-value < 0.05 and a log2 fold change > 1.0. Genes associated with 
the risk of IBD were downloaded from the genome-wide associa-
tion studies [GWAS] catalogue using the search term IBD on 29 
November 2016.17 Gene expression data for the 295 genes associ-
ated with IBD single nucleotide polymorphism [SNPs] was analysed 
by k-means clustering and three primary groups were identified. For 
interpretation, genes were further subdivided using the gene ontol-
ogy according to roles in inflammatory processes. The inflammatory 
properties of the genes were classified with the gene ontology as part 
of an inflammatory response [GO: 0006954] with subcategories for 
negative [GO: 0050728] and positive [GO: 0050729] regulators of 
inflammation. Heat maps were produced for each cluster to visualise 
the gene expression patterns of the GWAS associated genes in con-
junction with their regulatory and inflammatory roles.
3. Results
3.1. Patients
A standardised sampling method was used to collect mucosal biop-
sies from treatment-naïve UC patients [n  =  14] and control sam-
ples [n  =  16], as described above. The biopsies from UC patients 
showed mild to moderate disease activity [as defined by UCDAI], 
with clinical scores 7.23 ± standard deviation [SD] 2.45, and endo 
scores of 1.93 ± SD 0.27, estimated according to established clinical 
endoscopic and histological criteria, and as defined by the ECCO 
guidelines.12 The control group consisted of biopsies with normal 
colonoscopy, colon histology, and immunohistochemistry, and clini-
cal and endo scores  =  0. The biopsies of UC patients were taken 
from the sigmoid part of the colon. The gender distribution for both 
groups was almost equal, with nine males in the UC group and 11 
males in the control group, and five females in each group. The age 
distribution differed between the two groups, with 39.57 ± SD 15.24 
in the UC group, and 52.9 ± SD 16.9 in the control group. In order 
to obtain information about the inflammatory status of UC, TNF-α 
mRNA expression levels were measured by qPCR.14 Levels of TNF-α 
in control samples were estimated at 3663 ± SD 1973, and for UC 
samples 15907 ± SD 9623. A summary of all patient characteristics 
is depicted in Table 1.
3.2. Characterization of the whole transcriptome in 
treatment-naïve UC
The entire transcriptome representing treatment-naïve UC was 
established by RNA-Seq. Pre-processing of the sequencing data 
revealed expression of approximately 22 000 transcripts. Initial 
principal component analysis [PCA] of the 5000 most variable tran-
scripts revealed a clear distinction between UC and control samples 
along the first principal component with a 59.6% explained variance 
[Figure 1].
In order to estimate specific cell populations in UC and con-
trol tissue samples, a cell deconvolution method was applied as 
described. The deconvolutions were restricted to the following cell 
types: epithelial cells, monocytes, T cells, neutrophils, B cells/lym-
phoid cells, and myeloid cells. The results show a clear difference 
of cell fractions present in UC and control samples. An enrichment 
of monocytes, neutrophils, myeloid cells, T cells, and B/Lymphoid 
cells was observed in all UC samples, whereas the epithelial cell frac-
tion was decreased in almost all UC samples when compared with 
control samples. The results of the deconvolution experiments are 
depicted in Figure 2.
To further describe and analyse the entire transcriptome, sig-
nificantly differentially expressed transcripts were adjusted to 
p-value < 0.05 and a cut-off of log2 fold-change > 1.0 [n = 1480] 
was used for downstream analyses [Supplementary Data 1, available 
at ECCO-JCC online] whereof the top 30 differentially expressed 
genes [DEGs] with log2 fold-change > 3.5 are shown in Table 2. The 
differentially expressed gene transcripts were related to currently 
known 295 IBD susceptibility genes [Supplementary Figure 1, avail-
able at ECCO-JCC online] as revealed by GWAS [see Figure 3].18,19 
The identified gene transcripts have been annotated to different 
inflammatory processes and their transcriptional levels. Transcripts 
with unchanged expression are omitted in Figure 3. However, for a 
complete overview see Supplementary Figure 1. The data depicted 
in Figure 3 show 71 upregulated [24%] and eight downregulated 
transcripts [2.7%] linked with susceptibility to IBD. The annotation 
of the upregulated transcripts revealed genes involved in inflamma-
tory responses, like chemokine receptors [CCR5, CCR3, CXCR1, 
CXCR2], chemokine ligands [CXCL5, CXCL1, CXCL2, CXCL3, 
CXCL4 [PF4], and CCL20], tumour necrosis factor receptor super-
family members (TNFRSF5 [CD40] and TNFRSF9), interleukin 19 
[IL19], solute carrier family 11 member 1 [SLC11A1], intercellular 
adhesion molecule 1 [ICAM1], and signal transducer and activator 
of transcription 3 [STAT3], T cell specific antigens [CD28 and CD6], 
chemokine ligands [CCL2 and CCL11], oncostatin M [OSM] and 
its receptor oncostatin M receptor [OSMR], inflammatory bowel 
disease Protein 1 (NOD2 [IBD1]), and cyclooxygenase-2 (COX2 
[PTGS2]). Only one of the downregulated transcripts is involved in 
inflammatory response, epoxide hydrolase 2 [EPHX2]. In addition, 




















Figure  1. Principal component analysis [PCA]. Unsupervised PCA analysis 
showing the difference between UC [red] and control [blue] as well as 
gender, male control [blue square], female control [blue triangle], male UC 
[red square] and female UC [red triangle]. There is a 59.6% variance between 
UC and control samples, and an 8.2% variance between male and female 
samples. UC, ulcerative colitis.
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three significantly differentially expressed microRNAs [MIR155HG, 
MIR3936 and MIR4435-2HG] and 17 long non-coding RNAs 
[lncRNAs] have been identified [Supplementary Data 1].
The current study was compared with microarray- based stud-
ies carried out on two different Affymetrix-based microarray plat-
forms.20,21 Only well-characterised probes with Entrez IDs and 
official gene symbols were included in the comparison. Overall 
agreement between the studies when comparing UC patients and 
normal controls are shown in the Venn diagram [Supplementary 
Figure 2, available at ECCO-JCC online]. Only one gene, transmem-
brane 4 L6 family member 20 [TM4SF20], was found to be signifi-
cantly [log fold-change > 1 and p < 0.05] downregulated in our study 
but significantly upregulated in one of the others.21
3.3. Gender-specific transcription
PCA analysis did not only distinguished between UC and con-
trol samples [Figure  1] but could also distinguish transcripts to 
a lesser extent [variance 8.2%] and in a gender- specific man-
ner. The contrast matrix [[Nfemale - UCfemale] - [Nmale - UCmale]] was 
applied to determine differentially regulated genes with gender-
specific effects; 58 significantly differentially expressed genes with 
adjusted p-value  < 0.05 and log 2 FC  > 1.0 were identified [see 
Supplementary Data 2, available at ECCO-JCC online]. A boxplot 
of eight selected genes show gender-specific differences [Figure 4: 
Paneth cell specific defensin alpha 5 [DEFA5], serine protease 
8 [PRSS8], mucin 5B [MUC5B], phospholipase A2 group IIA 
[PLA2G2A], Fc fragment of IgG binding protein [FCGBP], regener-
ating family member 3 alpha [REG3A], interleukin 33 [IL33], and 
interferon alpha inducible protein 27 [IFI27]. The expression levels 
of the selected genes are higher in the UC group compared with the 
control group. However, the expression levels do not only show a 
difference between UC samples and control samples, but also show 
significant differences between UC samples and control samples 
for males and females. It is noted that thiosulphate sulphurtrans-
ferase [TST], mercaptopyruvate sulphurtransferase [MPST], and 
fucosyltransferase 2 [FUT2] are the only GWAS IBD susceptibility 
genes that are found to be expressed in a gender-specific manner 
[Supplementary Data 2; Figure 3].
4. Discussion
This study provides a unique, comprehensive, and quantitative 
record of high-resolution gene expression in a treatment-naïve UC 
patient population using next-generation RNA-Seq technology. 
Previous gene expression studies with UC patient material mostly 
used hybridisation-based methodologies like microarrays,7,22–25 and 
only one recent study reported RNA-Seq of human IBD patient 
material.11 RNA-Seq technology has some advantages over micro-
array technology, such as the ability of impartial detection of new 
transcripts and the easy detection of rare and low abundance tran-
scripts.10 In addition, RNA-Seq does not rely on pre-designed com-
plement-sequence detection probes, and is therefore free of issues 
associated with probe redundancy and annotation.26 Attempts were 
made in order to decipher if genes found in other studies20,21 including 
UC patients behaved differently in the present study [Supplementary 
Figure 2, available at ECCO-JCC online]. However, it is difficult to 
assign the variability between experiments to either effects of the 
technical platform or different severity of disease that was mild to 
moderate in our dataset and involved patients resistant to standard 
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Figure 2. Estimation of cell population between samples using cell deconvolution methods using the Bioconductor CellMix package. Epithelial markers [CDH1, 
EPCAM, L1CAM, and LAMA1] were added to the Immune Response In Silico [IRIS] marker list and weighted heavily to help estimate epithelial contribution. The 
blue dots indicate control samples and red dots indicate ulcerative colitis [UC] samples, respectively.
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In addition, recent UC transcriptome studies were performed 
by using non-stratified patient populations and material including 
both treated and treatment-naïve UC,11 which might have resulted 
in biased gene expression profiles. Therefore, in this study, the UC 
patient material was thoroughly stratified and only treatment-naïve 
patients were included [see Table 1 and Material and Methods]. This 
approach should provide an opportunity to investigate the transcrip-
tional profile of UC without the interference of any medications. 
Recent reports have shown that medication given to UC patients, 
such as immunosuppressant drugs, have short- and long-term side 
effects on the immune response.27 This treatment might introduce 
unwanted bias to experiments aiming to investigate the prior to 
medication status of UC patients. Furthermore, treatment-naïve UC 
transcriptomic signatures might also become important in order to 
decide individual treatment options for patients in the future. Our 
RNA-Seq revealed 1480 significantly DEGs [see Supplementary 
Data 1]. In the future, these DEGs could be used as a fingerprint for 
disease outcome and a beneficial treatment choice.
Human tissue samples are highly heterogeneous, and the amount 
of different cell types in a biopsy will have a certain impact on 
gene expression profiles. Therefore, and in order to determine the 
relative quantities of different immune cell types in the heterogene-
ous biopsies, cell deconvolution methods were applied [Figure  2]. 
As expected, the results clearly show and confirm that the innate 
and adaptive immune systems are triggered by inflammation as the 
fractions of monocytes, neutrophils, myeloid cells, T cells, and B/
lymphoid cells are found to be increased in UC [Figure  2]. These 
differences could very well due to inflammatory infiltrates; as for 
which cells contribute the most, we will need a much larger sample 
size and most likely confirmatory or parallel experiments using a 
different technique such as single cell sequencing. One interesting 
aspect with these data is that one could potentially identify various 
patterns. For example, UC patient no. 5 from the left [Figure 2] is 
rather high in monocytes and neutrophils but relatively low in T 
cells and B/lymphoid cells, but to decipher these types of patterns 
would require larger study populations. In concordance with these 
observations, the different inflammatory responses are reflected by 
increased expression of genes like leucocyte immunoglobulin-like 
receptors, cytokines/chemokines and their respective receptors and 
ligands, and T cell specific antigens [see Table 2; and Supplementary 
Data 1]. In particular, many of the DEGs that are involved in the 
control of bacterial proliferation showed increased expression dur-
ing mucosal inflammation, like regenerating family members [REGs] 
and defensins, which is in concordance with previous studies.7,28–32 
It is interesting to note that the here observed increased expression 
of factors predictive of response to anti-TNF-α therapy, oncostatin 
[OSM] and its receptor [OSMR], is of particular relevance for anti-
TNF-α resistant patients.33
Not surprisingly, the fraction of epithelial cells was lowered in 
UC [Figure  2]. Once the mucosal epithelium is compromised by 
inflammation, the fraction of functional epithelial cells diminishes, 
which then leads to a ‘leaky’ intestinal epithelium.34 The impaired 
ion transport and dysfunctional tight junctions in the epithelium 
are followed by chronic diarrhoea. In addition, increased levels of 
circulating TNF-α, and other cytokines lead to a rise of intestinal 
permeability, thereby causing oedema.35 This dysregulation of water 
and solute homeostasis has been suggested to play a role in UC. In 
concordance with our results, the expression levels of water chan-
nels like aquaporin 7 [AQP7] and aquaporin 8 [AQP8], have been 
shown to be reduced in the human intestinal mucosa in early stage 
IBD.36 Interestingly, aquaporin 9 [AQP9] was one of the most promi-
nent expressed genes in our UC patient material, which has not been 
reported before [Table 2]. AQP9 plays a role in specialised leukocyte 
functions such as immunological response and bactericidal activity, 
and is located in the membranes of tight junctions in the intestine.37 
In addition claudins, that are exclusively localised at tight junctions, 
were differentially expressed [Table 2], with claudin 2 [CLDN2] lev-
els being increased in UC samples, which is in accordance with for-
mer results.38–40 The ‘pore-forming’CLDN2, as a component of the 
tight junction, forms a water channel and thus mediates para-cellular 
water transport across the tight junctions in impaired epithelium.41 
In addition, the observed increase of CLDN2 correlates with UC 
severity on both protein and transcriptional levels.38 This might indi-
cate that CLND2 and AQP9 might share similar properties regard-
ing water transport. It is possible that like epithelial cells, other cells 
contribute to the elevated levels of CLDN and/or AQP9. However, 
no such information is available today. Cell sorting followed by sin-
gle cell sequencing might shed a light on this. The increased expres-
sion of CLDN and AQP9 might be a response to inflammation, 
fighting the disturbances in the epithelial barrier of the colon. Taken 
these results together, it could be hypothesised that CLDN2 together 
with AQP9 regulate tissue-specific pathophysiological properties of 
tight junctions in UC.
Intestinal infection generally leads to depletion of goblet cells and 
reduction in mucin synthesis and secretion, allowing pathogens to 
access the underlying epithelium.42 Interestingly, AQP9 could play 
another role for the synthesis and/or function of mucus, as recent 
immuno-histological studies have shown that AQP9 is expressed 
in a subset of mucin-producing goblet cells in the small intestine 
Table 2. Top 30 differentially expressed genes [DEGs] in treatment-
naïve ulcerative colitis [UC].
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and colon.37 However, mucin 2 [MUC2], which is the major con-
tributor to healthy lubrication of the mucosa, was not differentially 
expressed, which is in concordance with previous findings.43 In 
contrast, several other mucins showed increased expression in UC: 
mucin 1 [MUC1], mucin 16 [MUC16], mucin 4 [MUC4], mucin 5Ac 
[MUC5AC], and mucin 5B [MUC5B] [Table 2; and Supplementary 
Data 1]. Elevated levels of MUC1 and MUC4 in UC have been dem-
onstrated before.44,45 Contrary to results reported by others who 
have shown that expression of MUC5B is increased in colorectal 
cancer [CRC] but not in UC,46 we here report increased expression 
of MUC5B in UC. It is hereby noted that in normal colon, MUC5B 
has been shown to be secreted by colonic goblet cells; however it 
is expressed in minor quantities.47 In addition, we can report not 
only an increased but also gender-specific differences in the expres-
sion of MUC5B in UC, as discussed below [see also Figure 4; and 
Supplementary Data  2]. A  cytokine-induced mucin hypersecretion 
has been reported for MUC5AC in an in vitro model where expres-
sion increased in a TNF-α dose-dependent manner.48 This might 
be also the situation in our UC material, as elevated TNF-α lev-































































































Figure 3. Gene expression pattern across controls and UC patients of differentially expressed genes that are also reported as associated with GWAS risk SNPs. 
Colours indicate deviation from the mean expression level for each gene. Samples are colour-coded in the top bar according to gender and diagnosis [control, 
UC] and genes are colour-coded in the sidebar according to their inflammation-related gene ontology annotations. Transcripts with unchanged differential 
expression are omitted. UC, ulcerative colitis; GWAS, genome-wide association studies; SNPs. Single nucleotide polymorphisms.
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and Methods]. A role for MUC16 in UC, which showed the most 
prominent elevated expression levels [log2 FC 2.16] has not been 
established yet but has been recently proposed to be a biomarker for 
epithelial ovarian cancer.49
Recently, micro RNAs [miRNAs] and long non-coding RNAs 
[lncRNAs] have been addressed as having a role in IBD patho-
genesis.50,51 Three microRNAs have been identified in our data: 
MIR155HG, MIR3936, and MIR4435-2HG. It has been reported 
that MIR155 is involved in intestinal inflammation and immunity 
of UC by playing a role in the differentiation of B and T cells and 
dendritic cells, thereby contributing to the development of regula-
tory T cells.52–54 In addition, we observed 17 significantly differen-
tially expressed lncRNAs [Supplementary Data 1]. One functional 
relationship between UC and a particular lncRNA has been recently 
demonstrated.55 However, the relationship between UC and miR-
NAs and/or lncRNAs still remains unclear.
In order to characterise gene expression data from RNA-Seq 
further, one approach was to investigate how many differentially 
expressed genes are associated with IBD. Until today, approxi-
mately 300 SNPs associated with IBD have been discovered through 
GWAS.17 Although it is expected that this RNA-Seq study can-
not confirm GWAS findings, 79 of the significantly differentially 
expressed genes might be associated with IBD [see Table  2]. It is 
hereby noted that the GWAS susceptibility genes did not distinguish 
between UC and CD. However, although one should be cautious 
about assigning specificity to SNPs, since most GWAS studies are 
done comparing a patient population with a population of disease-
free controls and not between subtypes of the disease, some SNPs are 
indeed more strongly related to UC than CD and vice versa.56 Among 
our significantly differentially expressed genes, SP140 nuclear body 
protein [SP140] and strawberry notch homolog 2 [SBNO2] are 
located close to SNPs that are more strongly related to CD risk, and 
both of these genes have shown upregulated gene expression in UC 
[Supplementary Data 1].
Recently, gender-dependent differences in IBD pathologies have 
been proposed.57,58 Sex-stratified analysis of long-term complications 
of IBD show consistently higher risk of CRC in male IBD patients.59 
In addition, a recent population study reported that patients with 
UC are the high-risk group in incidence of CRC and that the risk is 
found to be higher in male than in female UC patients.60 The cur-
rent available information about gender-specific differences in UC 
is sparse and contradictory to some extent.61 It is a common belief 
that understanding gender differences in any disease is important for 
recognising the factors contributing to the disease expression and 
to determine its prognosis so that clinicians can offer an appropri-
ate medical therapy. However, molecular manifestations of a gender 
specificity for UC has not been established. We can for the first time 
show that gender differences on a molecular level occur not only 
between treatment-naïve UC patients [Figure 1], but also between 
control patients [Figure  4]. The most pronounced gender differ-
ences for UC were observed for mucin 5B [MUC5B], regenerating 
family member 3 alpha [REG3A], defensin A5 [DEFA5], and inter-
leukin 33 [IL33] [Figure 4]. In UC, IL33 expression is specifically 
increased and has been shown to be involved in the inflammatory 
tumour microenvironment and to contribute to the progression of 
CRC.62–64 In this context, it is interesting to note that IL33 is found to 
be more increased in male UC than in female UC. In addition, SNPs 
in human DEF5A may confer susceptibility to IBD.32 Furthermore, 
an upregulation of REG3A in colorectal cancer cells confers prolif-
eration and correlates with colorectal cancer risk.65 All these above-
mentioned genes were more elevated in male samples than in female 
samples and can therefore be considered as CRC risk factors in UC. 


































































Figure 4. A boxplot of selected genes that show gender-specific differences within a greater subset of UC versus control significant differentially expressed 
genes. F and M indicate control female and male samples, UC, ulcerative colitis. FUC and MUC indicate female and male UC samples.
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It is interesting to note that DEFA5, IL33, and REG3A showed also 
increased expression levels in control male samples when compared 
with control female samples. Taken all these observations together, 
a possible link between the expression of these genes and higher 
risk for the development of CRC following UC can be proposed 
for males. For some gender-specific genes, differential gene expres-
sion was observed between control male and female samples. Genes 
like serine protease 8 [PRSS8], Fc fragment of IgG binding protein 
[FCGBP], and interferon alpha-inducible protein 27 [IFAN27] 
showed increased expression in control female compared with con-
trol male samples. Interestingly, all these genes have been shown to 
convey protective properties in the mucosa: FCGBP has been shown 
to be involved in the maintenance of the mucosal structure as a gel-
like component of the mucosa; PRSS8 preserves colonic integrity and 
protects against inflammation, as has been demonstrated in DSS-
induced inflammation of mice; and IFN-α conveys antiviral activi-
ties.66–68 In addition, three gender-specific GWAS IBD susceptibility 
genes showed increased expression in female UC [Supplementary 
Data  2]. Two belonged to the family of sulphurtransferases, and 
both genes are involved in detoxification processes.69 The here 
observed expression of thiosulphate [TST]—and mercaptopyruvate 
[MPST] —sulphurtransferase is essential for sulphide detoxification 
in order to preserve healthy mucosa. Dysregulation of expression 
and/or activity of these enzymes may accompany development of 
UC.70 Here, fucosyltransferase 2 [FUT2] also might play a role in this 
regard, since this enzyme is involved in host-microbe interactions 
and has been shown to mediate interaction with intestinal micro-
biota, thereby influencing its composition.71–73
In conclusion, this study shows for the first time that the use of 
well-stratified treatment-naïve UC patient samples in combination 
with high-throughput RNA-Seq technology can reveal new molecu-
lar players that might be important in UC pathogenesis. Potentially 
significant might be the regulation of tissue-specific pathophysi-
ological properties of tight junctions in the mucosa as reflected by 
increased expression of AQP9 and CLDN2 and the expression of 
different mucins, particularly MUC5B and MUC16. In addition, 
a gender-dependent molecular manifestation could be established. 
The molecular patterns of UC revealed increased expression of 
genes involved in preserving mucosal integrity and detoxification 
of microbial-derived metabolites in females. The expression of anti-
microbial and cytotoxic genes in male UC patients may contribute 
to the higher risk for the development of CRC observed in males. 
These results can be useful for the development of new treatment 
and patient stratification strategies for UC. In addition, these expres-
sion patterns can be extremely useful if combined with UC remission 
data in the future.
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